WO2004037267A1 - Method and composition containing latanoprost for treating ocular hypertension and glaucoma - Google Patents
Method and composition containing latanoprost for treating ocular hypertension and glaucoma Download PDFInfo
- Publication number
- WO2004037267A1 WO2004037267A1 PCT/JP2003/013452 JP0313452W WO2004037267A1 WO 2004037267 A1 WO2004037267 A1 WO 2004037267A1 JP 0313452 W JP0313452 W JP 0313452W WO 2004037267 A1 WO2004037267 A1 WO 2004037267A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- ophthalmic composition
- ophthalmic
- benzalkonium chloride
- latanoprost
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03758746A EP1553953B1 (en) | 2002-10-24 | 2003-10-22 | Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
DK03758746.6T DK1553953T3 (en) | 2002-10-24 | 2003-10-22 | A method and composition comprising latanoprost for the treatment of ocular hypertension and glaucoma |
CA2502437A CA2502437C (en) | 2002-10-24 | 2003-10-22 | Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
DE60334134T DE60334134D1 (en) | 2002-10-24 | 2003-10-22 | UNGSMETHOD OF INCREASED AUGENINNENDRUCK AND GLAUKOM |
JP2005501572A JP2006503913A (en) | 2002-10-24 | 2003-10-22 | Methods and latanoprost-containing compositions for the treatment of ocular hypertension and glaucoma |
AT03758746T ATE480240T1 (en) | 2002-10-24 | 2003-10-22 | COMPOSITION CONTAINING LATANOPROST AND METHOD OF TREATMENT OF INCREASED EYE PRESSURE AND GLAUCOMA |
AU2003274734A AU2003274734A1 (en) | 2002-10-24 | 2003-10-22 | Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42077602P | 2002-10-24 | 2002-10-24 | |
US60/420,776 | 2002-10-24 | ||
US42104402P | 2002-10-25 | 2002-10-25 | |
US60/421,044 | 2002-10-25 | ||
US10/429,677 US7074827B2 (en) | 2002-10-24 | 2003-05-06 | Method for treating ocular hypertension and glaucoma |
US10/429,677 | 2003-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004037267A1 true WO2004037267A1 (en) | 2004-05-06 |
Family
ID=32110845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/013452 WO2004037267A1 (en) | 2002-10-24 | 2003-10-22 | Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
Country Status (9)
Country | Link |
---|---|
US (2) | US7074827B2 (en) |
EP (2) | EP2253322A1 (en) |
JP (2) | JP2006503913A (en) |
AT (1) | ATE480240T1 (en) |
AU (1) | AU2003274734A1 (en) |
CA (1) | CA2502437C (en) |
DE (1) | DE60334134D1 (en) |
DK (1) | DK1553953T3 (en) |
WO (1) | WO2004037267A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2269575A1 (en) | 2009-06-30 | 2011-01-05 | Santen Pharmaceutical Co., Ltd | Method for improving bioavailability of latanoprost |
US8722735B2 (en) | 2008-03-17 | 2014-05-13 | Alcon Research, Ltd. | Pharmaceutical compositions having desirable bioavailability |
US9999593B2 (en) | 2008-05-30 | 2018-06-19 | Santen Pharmaceutical Co., Ltd. | Method and composition for treating ocular hypertension and glaucoma |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004283091A1 (en) * | 2003-10-03 | 2005-05-06 | Allergan, Inc. | Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia |
ATE412400T1 (en) * | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | OIL-IN-WATER EMULSION WITH LOW CATIONIC AGENT CONCENTRATION AND POSITIVE ZETA POTENTIAL |
GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
DE102005035986B4 (en) * | 2005-07-28 | 2009-10-15 | Bausch & Lomb Incorporated | Sterile drippable multiphase emulsifier-free ophthalmic preparation |
CN101282714B (en) * | 2005-10-10 | 2012-12-12 | 诺瓦加利制药公司 | Ophthalmic emulsions containing prostaglandins |
CA2681668C (en) | 2006-03-23 | 2014-04-01 | Michael S. Singer | Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat |
TWI394564B (en) * | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | Self-preserved aqueous pharmaceutical compositions |
EP2066300B2 (en) * | 2006-09-28 | 2019-01-23 | Novartis Ag | Self-preserved aqueous pharmaceutical compositions |
FR2912207B1 (en) * | 2007-02-01 | 2012-10-26 | Air Liquide | PROCESS AND APPARATUS FOR PRODUCING CARBON MONOXIDE BY CRYOGENIC DISTILLATION |
WO2008096804A1 (en) * | 2007-02-07 | 2008-08-14 | Teika Pharmaceutical Co., Ltd. | Eye drop preparation comprising latanoprost |
JP2008247828A (en) * | 2007-03-30 | 2008-10-16 | Wakamoto Pharmaceut Co Ltd | Aqueous medicine composition containing latanoprost |
FR2918891B1 (en) * | 2007-07-20 | 2009-09-25 | Thea Sa Lab | OPHTHALMIC SOLUTION BASED ON PROSTAGLANDINS WITHOUT PRESERVATIVE |
JP2009040727A (en) * | 2007-08-09 | 2009-02-26 | Towa Yakuhin Kk | Stable eye lotion containing latanoprost as active ingredient |
JP5327809B2 (en) * | 2007-08-29 | 2013-10-30 | わかもと製薬株式会社 | Latanoprost-containing aqueous pharmaceutical composition |
MX2007011165A (en) * | 2007-09-12 | 2009-03-11 | Arturo Jimenez Bayardo | Pharmaceutically stable compound consisting of timolol, dorzolamide and brimonidine. |
JP5583111B2 (en) * | 2008-03-17 | 2014-09-03 | アルコン リサーチ, リミテッド | Aqueous pharmaceutical composition containing a borate-polyol complex |
EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
JP2010275259A (en) * | 2009-05-29 | 2010-12-09 | Toa Yakuhin Kk | Uniform and stable latanoprost ophthalmic liquid composition |
TWI489997B (en) * | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | Aqueous pharmaceutical compositions containing borate-polyol complexes |
EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
KR101656121B1 (en) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | Pharmaceutical composition for treatment of increased intraocular pressure |
FR2961694B1 (en) * | 2010-06-29 | 2013-01-25 | Thea Lab | POLYMERIC DELIVERY SYSTEM FOR NON-VISCOUS SOLUTION BASED ON PROSTAGLANDIN WITHOUT PRESERVATIVE |
WO2012015996A2 (en) * | 2010-07-29 | 2012-02-02 | Allergan, Inc. | Preservative free bimatoprost solutions |
CA2807081C (en) * | 2010-07-29 | 2018-09-18 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
EP2452669A1 (en) | 2010-10-29 | 2012-05-16 | Omnivision GmbH | Ophthalmic composition |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
EP3378480A1 (en) | 2011-01-19 | 2018-09-26 | Topokine Therapeutics, Inc. | Methods and compositions for treating obesity |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
CN107970506B (en) * | 2012-04-10 | 2020-06-16 | 艾诺维亚股份有限公司 | Use of directed droplet streams with controllable droplet charge for the preparation of a medicament |
EA201491906A1 (en) | 2012-04-20 | 2015-03-31 | Айновиа, Инк. | SPRAYING EJECTOR DEVICE AND METHODS OF ITS USE |
KR102168906B1 (en) | 2012-05-14 | 2020-10-22 | 아이노비아 인코포레이티드 | Laminar flow droplet generator device and methods of use |
EP2849949A4 (en) | 2012-05-15 | 2017-07-26 | Eyenovia, Inc. | Ejector devices, methods, drivers, and circuits therefor |
JP6039152B2 (en) | 2012-09-12 | 2016-12-07 | ノバリック ゲーエムベーハー | Semi-fluorinated alkane composition |
CA2869676C (en) | 2012-11-21 | 2015-06-23 | Topokine Therapeutics, Inc. | Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
NO2753788T3 (en) | 2013-05-10 | 2018-06-16 | ||
US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
TW201542196A (en) * | 2013-08-26 | 2015-11-16 | Rohto Pharma | Ophthalmic formulation |
GR1008483B (en) * | 2013-12-23 | 2015-05-12 | Rafarm Α.Ε.Β.Ε., | Ophthalmic pharmaceutiacl composition and process for the preparation thereof |
US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
US10326270B2 (en) | 2014-08-05 | 2019-06-18 | Sony Corporation | DC power transmission device, DC power reception device, and DC power transmission system |
DE202016008738U1 (en) | 2015-09-30 | 2019-04-09 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
CN108349855B (en) | 2015-09-30 | 2021-07-20 | 诺瓦利克有限责任公司 | Semi-fluorinated compounds for ophthalmic administration |
GR1009040B (en) * | 2016-04-19 | 2017-05-19 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Preservative free pharmaceutical ophthalmic compositions |
ES2763121T3 (en) | 2016-06-23 | 2020-05-27 | Novaliq Gmbh | Topical administration method |
CN116172987A (en) | 2016-09-22 | 2023-05-30 | 诺瓦利克有限责任公司 | Pharmaceutical composition for treating blepharitis |
US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
CN111372566A (en) | 2017-09-27 | 2020-07-03 | 诺瓦利克有限责任公司 | Ophthalmic composition comprising latanoprost for treating ocular diseases |
CN111182893A (en) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | Ophthalmic composition comprising F6H8 |
SG11202007858VA (en) | 2018-03-02 | 2020-09-29 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
PL3886799T3 (en) | 2019-08-07 | 2024-03-18 | Aneira Pharma, Inc. | Compositions for the treatment of hair loss |
JP2022120120A (en) * | 2022-06-13 | 2022-08-17 | 東亜薬品株式会社 | OPHTHALMOLOGIC AQUEOUS COMPOSITION AND METHOD FOR INHIBITING DECREASE IN CONTENT OF PROSTAGLANDIN F2α DERIVATIVE |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001095913A1 (en) | 2000-06-13 | 2001-12-20 | Synphora Ab | Methods and compositions for the prevention of myopia |
WO2002038158A1 (en) | 2000-11-13 | 2002-05-16 | Pharmacia Ab | Improved treatment |
US20020103255A1 (en) | 1997-12-19 | 2002-08-01 | Hellberg Mark R. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
EP1532981A1 (en) | 2002-08-23 | 2005-05-25 | Santen Pharmaceutical Co., Ltd. | Stable eye drops containing latanoprost as the active ingredient |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002553A1 (en) * | 1988-09-06 | 1990-03-22 | Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
WO1997023225A1 (en) | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
JPH10259179A (en) * | 1996-09-19 | 1998-09-29 | Santen Pharmaceut Co Ltd | Prostaglandins having multi-substituted aryloxy groups and their use |
AR002194A1 (en) | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | COMPUTERIZED INSTRUMENT FOR THE ANALYSIS OF MOVEMENT. |
JP4000505B2 (en) * | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | Concomitant medications for treating glaucoma |
US20020035148A1 (en) * | 2000-07-20 | 2002-03-21 | Ryuji Ueno | Treatment of ocular hypertension |
PT1321144E (en) | 2000-09-13 | 2011-03-10 | Santen Pharmaceutical Co Ltd | Eye drops |
JP3876355B2 (en) * | 2000-09-13 | 2007-01-31 | 参天製薬株式会社 | Ophthalmic solution |
US8549114B2 (en) * | 2002-06-12 | 2013-10-01 | Bladelogic, Inc. | Method and system for model-based heterogeneous server configuration management |
KR20050057251A (en) | 2002-09-09 | 2005-06-16 | 산텐 세이야꾸 가부시키가이샤 | Transparent eye drops containing latanoprost |
-
2003
- 2003-05-06 US US10/429,677 patent/US7074827B2/en not_active Expired - Fee Related
- 2003-10-22 WO PCT/JP2003/013452 patent/WO2004037267A1/en active Application Filing
- 2003-10-22 JP JP2005501572A patent/JP2006503913A/en active Pending
- 2003-10-22 EP EP10171708A patent/EP2253322A1/en not_active Withdrawn
- 2003-10-22 AU AU2003274734A patent/AU2003274734A1/en not_active Abandoned
- 2003-10-22 DK DK03758746.6T patent/DK1553953T3/en active
- 2003-10-22 EP EP03758746A patent/EP1553953B1/en not_active Expired - Lifetime
- 2003-10-22 AT AT03758746T patent/ATE480240T1/en active
- 2003-10-22 DE DE60334134T patent/DE60334134D1/en not_active Expired - Lifetime
- 2003-10-22 CA CA2502437A patent/CA2502437C/en not_active Expired - Fee Related
-
2006
- 2006-05-23 US US11/438,290 patent/US8673973B2/en not_active Expired - Fee Related
-
2012
- 2012-05-31 JP JP2012125019A patent/JP2012162570A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020103255A1 (en) | 1997-12-19 | 2002-08-01 | Hellberg Mark R. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
WO2001095913A1 (en) | 2000-06-13 | 2001-12-20 | Synphora Ab | Methods and compositions for the prevention of myopia |
WO2002038158A1 (en) | 2000-11-13 | 2002-05-16 | Pharmacia Ab | Improved treatment |
EP1532981A1 (en) | 2002-08-23 | 2005-05-25 | Santen Pharmaceutical Co., Ltd. | Stable eye drops containing latanoprost as the active ingredient |
Non-Patent Citations (2)
Title |
---|
COSTAGLIOLA C ET AL: "Ocular surface changes induced by topical application of latanoprost and timolol: A short-term study in glaucomatous patients with and without allergic conjunctivitis", GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 2001 GERMANY, vol. 239, no. 11, 2001, pages 809 - 814, XP002272140, ISSN: 0721-832X * |
COSTAGLIOLA ET AL., GRAEFE'S ARCH CLIN EXP OPHTHALMOL, vol. 239, 2001, pages 809 - 814 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8722735B2 (en) | 2008-03-17 | 2014-05-13 | Alcon Research, Ltd. | Pharmaceutical compositions having desirable bioavailability |
US8754123B2 (en) | 2008-03-17 | 2014-06-17 | Alcon Research, Ltd. | Pharmaceutical compositions having desirable bioavailability |
US9144561B2 (en) | 2008-03-17 | 2015-09-29 | Alcon Research, Ltd. | Pharmaceutical compositions having desirable bioavailability |
US9999593B2 (en) | 2008-05-30 | 2018-06-19 | Santen Pharmaceutical Co., Ltd. | Method and composition for treating ocular hypertension and glaucoma |
US10864159B2 (en) | 2008-05-30 | 2020-12-15 | Santen Pharmaceutical Co., Ltd. | Method and composition for treating ocular hypertension and glaucoma |
EP2269575A1 (en) | 2009-06-30 | 2011-01-05 | Santen Pharmaceutical Co., Ltd | Method for improving bioavailability of latanoprost |
Also Published As
Publication number | Publication date |
---|---|
US8673973B2 (en) | 2014-03-18 |
US20040082660A1 (en) | 2004-04-29 |
CA2502437C (en) | 2012-07-17 |
US7074827B2 (en) | 2006-07-11 |
DE60334134D1 (en) | 2010-10-21 |
JP2006503913A (en) | 2006-02-02 |
AU2003274734A1 (en) | 2004-05-13 |
ATE480240T1 (en) | 2010-09-15 |
EP2253322A1 (en) | 2010-11-24 |
JP2012162570A (en) | 2012-08-30 |
EP1553953B1 (en) | 2010-09-08 |
CA2502437A1 (en) | 2004-05-06 |
DK1553953T3 (en) | 2010-10-25 |
EP1553953A1 (en) | 2005-07-20 |
US20060205725A1 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2502437C (en) | Method and composition containing latanoprost for treating ocular hypertension and glaucoma | |
US6271224B1 (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia | |
RU2563125C2 (en) | Aqueous pharmaceutical compositions, containing borate-polyol complexes | |
US10792288B2 (en) | Preservative free brimonidine and timolol solutions | |
US20100041671A1 (en) | Methods for treating glaucoma | |
US9119827B2 (en) | Ophthalmic composition | |
KR20140056280A (en) | Fixed dose combination of bimatoprost and brimonidine | |
EP2316420B1 (en) | Topical ophthalmic composition to reduce pain | |
US5438060A (en) | Method of reducing elevated intraocular pressure | |
JP2021518352A (en) | Pharmaceutical composition containing timolol | |
CA2274708A1 (en) | Remedial composition for intraocular hypertension or glaucoma | |
US20140228338A1 (en) | Topical ocular analgesic agents | |
KR20230145458A (en) | Aqueous pharmaceutical composition containing ursodeoxycholic acid or its salt | |
EP0205606B1 (en) | Pharmaceutical compositions and their use as mydriatics | |
US20120232139A1 (en) | Composition for ocular topical administration treatment ocular hypertension and glaucoma | |
EP0728480A1 (en) | Use of ifenprodil for treatment of elevated intraocular pressure | |
JP7118579B1 (en) | Aqueous composition containing epinastine or its salt | |
JP6963651B2 (en) | Aqueous composition containing epinastine or a salt thereof | |
ES2349699T3 (en) | METHOD AND COMPOSITION CONTAINING LATANOPROST TO TREAT EYE HYPERTENSION AND GLAUCOMA. | |
WO2024034592A1 (en) | Aqueous pharmaceutical composition containing udca or salt thereof | |
KR20220089106A (en) | Eye drop composition comprising corzolamide or polysorbate 80 as an active ingredient | |
WO2019123266A1 (en) | Ophthalmic composition having a prostaglandin and a beta-blocker | |
WO2000043015A1 (en) | Eye drops | |
WO1996007406A1 (en) | Combination of levobunolol and dipivefrin for ophthalmic use | |
WO1995033456A2 (en) | Reducing intraocular pressure using aryloxy- and aryl-acetic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003758746 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005501572 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2502437 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2003758746 Country of ref document: EP |